Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emergencies of calcium homeostasis.

× No keyword cloud information.

42 in total

Review 1. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.

Authors: L C Hofbauer
Journal: Eur J Endocrinol Date: 1999-09 Impact factor: 6.664

Review 2. Tumor-induced hypercalcemia in a patient with extensive soft tissue sarcoma: effects of bisphosphonate therapy and surgery.

Authors: V Oleffe; J C Dumon; J J Body
Journal: J Surg Oncol Date: 1996-10 Impact factor: 3.454

3. Hypercalcemia associated with silicone-induced granulomas.

Authors: G A Kozeny; A L Barbato; V K Bansal; L L Vertuno; J E Hano
Journal: N Engl J Med Date: 1984-10-25 Impact factor: 91.245

Review 4. Diagnosis and treatment of hyperparathyroidism.

Authors: R Marcus
Journal: Rev Endocr Metab Disord Date: 2000-11 Impact factor: 6.514

5. Technical and clinical validation of a new immunoradiometric assay for human osteocalcin.

Authors: J C Dumon; H Wantier; F Mathieu; M Mantia; J J Body
Journal: Eur J Endocrinol Date: 1996-08 Impact factor: 6.664

6. Studies of the hypercalcaemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxy vitamin D3.

Authors: L M Sandler; C G Winearls; L J Fraher; T L Clemens; R Smith; J L O'Riordan
Journal: Q J Med Date: 1984

7. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.

Authors: H Gurney; V Grill; T J Martin
Journal: Lancet Date: 1993-06-26 Impact factor: 79.321

8. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.

Authors: S R Nussbaum; J Younger; C J Vandepol; R F Gagel; M A Zubler; R Chapman; I C Henderson; L E Mallette
Journal: Am J Med Date: 1993-09 Impact factor: 4.965

9. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.

Authors: J R Green; K Müller; K A Jaeggi
Journal: J Bone Miner Res Date: 1994-05 Impact factor: 6.741

10. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.

Authors: J Walls; W A Ratcliffe; A Howell; N J Bundred
Journal: Br J Cancer Date: 1994-07 Impact factor: 7.640

6 in total

1. Evaluation and therapy of hypercalcemia.

Authors: Nadia Khoury; Kim A Carmichael
Journal: Mo Med Date: 2011 Mar-Apr

Review 2. [Management of symptomatic bone metastases in urologic malignancies].

Authors: N Rolfes; G Lümmen
Journal: Urologe A Date: 2014-06 Impact factor: 0.639

Review 3. Hypocalcemia: updates in diagnosis and management for primary care.

Authors: Jeremy Fong; Aliya Khan
Journal: Can Fam Physician Date: 2012-02 Impact factor: 3.275

Review 4. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.

Authors: Jean-Jacques Body; Roger von Moos; Daniela Niepel; Bertrand Tombal
Journal: BMC Urol Date: 2018-09-20 Impact factor: 2.264

5. Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing?

Authors: A Catalano; D Chilà; F Bellone; G Nicocia; G Martino; I Loddo; N Morabito; S Benvenga; S Loddo
Journal: J Clin Transl Endocrinol Date: 2018-05-29

6. Atypical Parathyroid Adenoma Complicated with Protracted Hungry Bone Syndrome after Surgery: A Case Report and Literature Review.

Authors: Óscar Alfredo Juárez-León; Miguel Ángel Gómez-Sámano; Daniel Cuevas-Ramos; Paloma Almeda-Valdés; Manuel Alejandro López-Flores A La Torre; Alfredo Adolfo Reza-Albarrán; Francisco Javier Gómez-Pérez
Journal: Case Rep Endocrinol Date: 2015-11-12

6 in total